Human Mesenchymal Stem Cell (hMSC) Donor Potency Selection for the "First in Cystic Fibrosis" Phase I Clinical Trial (CEASE-CF)
Human Mesenchymal Stem Cell (hMSC) immunotherapy has been shown to provide both anti-inflammatory and anti-microbial effectiveness in a variety of diseases. The clinical potency of hMSCs is based upon an initial direct hMSC effect on the pro-inflammatory and anti-microbial pathophysiology as well as...
Saved in:
Main Authors: | Tracey L. Bonfield (Author), Morgan T. Sutton (Author), David R. Fletcher (Author), Jane Reese-Koc (Author), Erica A. Roesch (Author), Hillard M. Lazarus (Author), James F. Chmiel (Author), Arnold I. Caplan (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Theoretical and Practical Issues That Are Relevant When Scaling Up hMSC Microcarrier Production Processes
by: Valentin Jossen, et al.
Published: (2016) -
Enhancing Cystic Fibrosis Immune Regulation
by: Anna M. van Heeckeren, et al.
Published: (2021) -
Principal Criteria for Evaluating the Quality, Safety and Efficacy of hMSC-Based Products in Clinical Practice: Current Approaches and Challenges
by: Juan Antonio Guadix, et al.
Published: (2019) -
Antimicrobial Properties of Mesenchymal Stem Cells: Therapeutic Potential for Cystic Fibrosis Infection, and Treatment
by: Morgan T. Sutton, et al.
Published: (2016) -
Cease firing
by: Johnston, Mary, 1870-1936; Wyeth, N. C. (Newell Convers), 1882-1945 [Illustrator]